NIH RFA-NS-26-001: Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)

NIH RFA-NS-26-001: Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)

If your team is already working at the interface between clinical operations, trial science, and translational neuroscience, this 2026 NIH opportunity is one of the few mechanisms that explicitly starts from real-world treatment access constraints and asks applicants to design studies around them. The NOFO is not a standard hypothesis-driven basic science call with a broad disease focus. It is a structured, mission-oriented cooperative agreement designed to use expanded-access (EA) pathways for ALS while avoiding overlap with ongoing pivotal trials.

Key details at a glance

What this opportunity is really about

The purpose stated in the official notice is straightforward: support scientifically rigorous research using data from expanded-access programs for investigational ALS drugs or biologics. The practical implication is important. The NOFO is not funding standard commercialized late-stage R01-style grants by default. It targets a specific pathway under FDA and NIH authority where some patient populations cannot enter standard trials for safety, inclusion, or eligibility reasons.

In this context, “intermediate-size population” is a term with operational consequences. It is not a tiny pilot cohort and not an uncontrolled broad open-label expansion. The NOFO describes populations not eligible for ongoing efficacy trials and explicitly links to FDA-regulated expanded-access pathways (including the role of 21 U.S.C. 360bbb and FDA clinical frameworks). The opportunity therefore tends to be strong for teams that already understand protocol governance, data curation constraints, and ethical oversight around compassionate treatment pathways.

Another important design cue: this opportunity was introduced under the broader ACT for ALS framework and sits in NINDS’ portfolio of translational and clinical infrastructure-minded grants. That matters because reviewers and program staff will often prioritize teams with clear execution plans over teams with only a strong publication narrative.

Why it matters for 2026 and 2027 applicants

RFA-NS-26-001 is explicitly active in 2026 and the same NOFO text includes a multi-date key-date pattern, with first-cycle dates in June and November 2026 and additional windows in 2027. For applicants, this means two practical implications:

1. If your team is not portal-ready in 2026, there may still be another entry point, but the first meaningful window can carry momentum and often helps shape later submissions.
2. You should monitor all dates as posted in the official NOFO page, because multi-cycle NIH programs frequently tighten internal scoring patterns over time.

The program is not framed as a one-off one-shot with no repeats. It is a federal mechanism with recurring deadlines and explicit review cycles. If your institution can only submit one high-quality application this year, use the first full-cycle timing to build internal evidence and avoid rushed rework.

Who this opportunity fits

This opportunity is for research groups that can operate in three linked domains at once:

• Clinical operations: you need at least one active, qualifying phase 2/3 or phase 3 efficacy trial relationship with an investigational ALS therapy under a U.S. small business sponsor.
• Data execution: the program is about generating and analyzing expanded-access data, so your protocol must explain collection pathways, harmonization, and quality control.
• Cross-institution coordination: the application is effectively stronger when multisite execution is realistic and not merely aspirational.

The NOFO broadens institutional eligibility to many U.S.-based organization types: public/private higher education, nonprofits (including IRS status variants), small and non-small for-profits, local and state governments, Indian/Native American entities, housing authorities, faith or community-based organizations, and regional organizations.

That said, this broad list is narrowed by one critical rule: applicants must be clinical trial sites involved in phase 2/3 or phase 3 efficacy trials for an eligible ALS investigational product sponsored by a U.S.-based small business concern (as defined under SBA standards). Foreign organizations and foreign components are not eligible. If your collaboration team is international, keep the U.S. participation structure explicit and compliant.

A practical way to test fit is this simple filter:

• Do we already work with a qualifying NIH-sponsored ALS therapeutic EA pathway? If not, this may be a stretch.
• Can our team produce a proposal that uses real-world EA-derived data while preserving trial safety and regulatory boundaries? If no, build that first.
• Can we show operational control over protocol logistics at participating sites? If no, this likely fails on feasibility.

Key requirements, in practical order

1) Confirm participation structure

The opportunity requires sites tied to qualifying phase 2/3 or 3 efficacy trials. Do not assume a generalized ALS program is enough. The NOFO explicitly asks for clinical-trial-site-level participation logic with qualifying sponsors.

To avoid ineligibility, your concept statement should include:

• trial phase and sponsor details,
• whether the sponsor is a U.S.-based small business concern,
• current patient ineligibility rationale (why this population cannot be enrolled in ongoing trials),
• the role of your site(s) in delivering treatment and data.

2) Use the right grant mechanism expectations

The mechanism is U01 cooperative agreement. In NIH practice, that usually implies more structured interaction with NIH program staff than a standard award. Your proposal should show not just what you plan scientifically, but how you plan to execute and report.

3) Respect eligibility and boundaries

The NOFO states non-domestic entities are not eligible and non-U.S. components are excluded in NIH terms. Put this in your internal checklist and avoid writing language that suggests a broader international consortium unless the U.S. application structure is unmistakably clean.

4) Budget and effort realism

The total program budget is listed at $40,000,000 and expected awards are 4, but individual award minimum and maximum values were not specified in the listing. If your current draft contains per-site budget assumptions tied to assumed award sizes, mark those as placeholders and adjust after peer review with your office.

5) Time and administrative readiness

All submissions are due by 5:00 PM local applicant time. Applications must be corrected through Grants.gov before the due-time. Late corrections are late; out-of-date data is a common avoidable issue.

If you are not already using the required systems, use this requirement as a hard go-live date for internal testing:

• Submit your forms through ASSIST, Grants.gov Workspace, or approved institutional route,
• Verify errors and warnings are resolved before final upload,
• Review submission in eRA Commons.

Step-by-step preparation roadmap (for a 2026 submission)

6–10 weeks before first due date

Draft the clinical and data scope first. Many teams accidentally open with hypothesis framing and only later add trial mechanics, which is reversed for this NOFO.

Build these components in parallel:

1. Eligibility evidence pack: trial relationship docs, institutional compliance status, site approvals.
2. Data plan: collection workflow, transfer path, harmonization map, QA checks.
3. Governance and ethics map: IRB/IEC responsibilities, consent model constraints, reporting obligations.
4. Regulatory alignment: FDA expanded access pathway interpretation, product and trial identifiers, any restrictions.

4–6 weeks before

Turn the draft into a reviewable package:

• Expand scientific rationale to include why intermediate-size EA data changes decision quality.
• Define analysis plan in enough detail to show interpretable outputs, not just feasibility claims.
• Add timeline and staffing that reflect clinical and translational sequencing.

2 weeks before

Submit a complete preflight to an internal review group that includes grants office, compliance, and data security representation.

Given the NOFO deadline behavior, you should target a “ready for correction” state before internal approvals are finalized. The goal is to avoid a final-day scramble caused by required system corrections.

Final 48–72 hours

Finalize application metadata, upload in Grants.gov path, resolve all errors, and log a screenshot/checklist entry for submission verification before the final deadline. This avoids the common problem of “we submitted but did not verify” failures.

Common mistakes and how to avoid them

Mistake 1: Treating this like a standard trial application

This is not a trial enrollment application or a straightforward treatment-development grant. It is a research grant around EA-derived evidence in a defined population segment. If your Specific Aims does not explain how trial access constraints produce scientific insight, it reads like a protocol for a different funding scheme.

Mistake 2: Assuming all ALS sites are automatically eligible

The NOFO ties eligibility to phase 2/3 or 3 efficacy trial context plus a qualifying sponsor condition. Missing this in the narrative is a fast rejection risk.

Mistake 3: Ignoring foreign component boundaries

Even well-designed collaborations fail on compliance if foreign components are not handled as allowed components under NIH rules. Keep your consortium architecture U.S.-compliant at submission stage.

Mistake 4: Underestimating submission mechanics

A common NIH timing failure in this program is treating the content as “good enough” before system submission is validated. The NOFO language is explicit that applications must be corrected by deadline; delayed corrections are late.

Mistake 5: Overpromising project period

The NOFO caps project period at 4 years. Any proposed workplan must be explicit about what will be completed at each stage in that time.

Mistake 6: Weak data operations plan

Reviewers and program staff can identify whether biospecimen and data handling assumptions are operationally real. Because this program is about data from EA protocols, this is not optional.

Eligibility FAQ (quick, practical)

Is there a minimum award amount?

Not specified on the opportunity listing. Program-wide funding is stated as $40,000,000 with about four expected awards.

Can international institutions apply?

No foreign organizations or non-U.S. components are listed as eligible under the NOFO notes.

What is the mechanism?

U01 Research Project–style cooperative agreement.

Are commercial sponsors restricted?

The NOFO indicates clinical sites must connect to phase 2/3 or phase 3 efficacy trials with a U.S.-based small business sponsor, but other organizational types can be involved in the broader application ecosystem when meeting eligibility language.

Is cost sharing required?

No cost sharing is required.

Can applications be submitted after the listed dates if the portal is open?

The NOFO sets strict due dates and states that late applications are not accepted. Err on the side of early submission with correction windows.

How reviewer teams will likely score this kind of proposal

Even where score rubrics are not fully described in public summaries, you can infer the program’s likely review expectations from the notice design:

• Programmatic relevance: Does the project use EA-derived data to answer a question that otherwise remains unanswered in standard trials?
• Clinical realism: Is the relationship to the qualifying trial sponsor and phase environment defensible and documented?
• Data validity: Are collection, harmonization, and analysis workflows coherent and feasible?
• Operational rigor: Is governance, oversight, and site execution realistic?
• Regulatory discipline: Do ethics and reporting procedures reflect NIH and FDA pathways?

A strong application answers these directly in the first two pages and then supports each claim with method and team structure in depth.

Strategic fit vs adjacent opportunities

If your idea is primarily mechanistic ALS biology with no clear EA-data component, this is likely too far afield. If your idea is broad social or implementation research with no trial-site link, it may be similarly misaligned.

Strong alternatives are often:

• clinical data harmonization proposals already linked to ALS treatment access pathways,
• studies where treatment access creates meaningful new endpoints,
• proposals that can convert treatment-use variability into scientifically interpretable signals.

Weaker alternatives are:

• generic ALS care studies,
• purely preclinical work with no EA pathway integration,
• teams that cannot show trial-collaboration readiness by submission time.

Official links

• Official opportunity listing: https://simpler.grants.gov/opportunity/0e61d658-5a10-46a1-9449-93a3c1ed768b
• NIH NOFO full text (document link from listing): https://files.simpler.grants.gov/opportunities/0e61d658-5a10-46a1-9449-93a3c1ed768b/attachments/1f62fa6a-b954-4157-bd82-72fe1e8a0e0b/RFA-NS-26-001-Full-Announcement.html
• NIH grants policy and submissions baseline: https://grants.nih.gov/policy/policy.htm

Final planning note

Use this call as a readiness test for translational grant execution. If your team’s draft can pass internal pre-review twice—once for eligibility and once for submission mechanics—the review probability improves significantly. The underlying science is important; the execution quality is decisive.